Artelo Biosciences Inc. (ARTLW)
Artelo Biosciences Statistics
Share Statistics
Artelo Biosciences has 2.33M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 2.33M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 1.58% |
| Shares Floating | 3.2M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.83 and the forward PE ratio is null. Artelo Biosciences's PEG ratio is 0.02.
| PE Ratio | -0.83 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.42 |
| P/FCF Ratio | -1.02 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Artelo Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.36, with a Debt / Equity ratio of 0.
| Current Ratio | 18.36 |
| Quick Ratio | 18.36 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | -2057.4 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.97M |
| Employee Count | 5 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -209K |
| Effective Tax Rate | 2.07% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 1.25, so Artelo Biosciences's price volatility has been higher than the market average.
| Beta | 1.25 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.05 |
| Relative Strength Index (RSI) | 41.24 |
| Average Volume (20 Days) | - |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -10.29M |
| Net Income | -9.87M |
| EBITDA | -10.29M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -3.49 |
Balance Sheet
The company has 6.89M in cash and 63K in debt, giving a net cash position of 6.83M.
| Cash & Cash Equivalents | 6.89M |
| Total Debt | 63K |
| Net Cash | 6.83M |
| Retained Earnings | -31.02M |
| Total Assets | 15.5M |
| Working Capital | 12.51M |
Cash Flow
In the last 12 months, operating cash flow was -8.01M and capital expenditures 0, giving a free cash flow of -8.01M.
| Operating Cash Flow | -8.01M |
| Capital Expenditures | 0 |
| Free Cash Flow | -8.01M |
| FCF Per Share | -2.83 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ARTLW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for ARTLW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -4.53 |
| Piotroski F-Score | 2 |